Dydrogesterone Market In India: Shifting Prescriber Trends, Evolving Gynecologist Mindset, Innovator Setbacks, The Rise Of Generic Competition, And Strategic Outlook

KIRTAN PATEL , RIYA NANDU , DIPAK VAGEHLA , Meghna PateL , POOJA CHAVADA

Dydrogesterone, Progestogen Market, Innovator vs Generic, Gynecologist Prescription Trends, Progestin Therapy, India Pharmaceutical Landscape, Market Access Strategy, Hormonal Therapy in Gynecology, Bioequivalence, Reproductive Health, Prescription Behavior, Healthcare Economics India, Brand Erosion and Generic Surge

The Indian progestogen market is undergoing a significant transformation, marked by a dynamic interplay between innovator brands, the rapid emergence of generics, and evolving prescribing behavior among gynaecologists. Dydrogesterone, a synthetic progestogen traditionally dominated by Abbott's innovator brand Duphaston, has witnessed a dramatic shift in market dynamics following its patent expiry in 2021. With over 50 generic brands entering the segment within two years, the competitive landscape has broadened, creating both opportunities and challenges for stakeholders across the pharmaceutical value chain. Abbott's Duphaston, recognised for its high-quality manufacturing in the Netherlands and robust clinical backing, retained its position as a market leader with an estimated INR350 crore annual revenue in FY2023. However, the influx of cost-effective generics, produced locally by companies like Mankind, Zydus, Emcure, and others, has fueled a shift in gynaecologists' preference, particularly in Tier 2 and Tier 3 cities, where affordability and accessibility are paramount. Collectively, generics have captured approximately 42% of the dydrogesterone market, with combined sales surpassing INR250 crore in just two years. This market evolution is further influenced by multiple forces. On one hand, gynecologists in urban centers continue to favor innovator brands for their superior clinical outcomes in high-risk pregnancies and infertility treatments. On the other hand, the rise in patient load, pricing sensitivity, and growing influence of field representatives are pushing many gynecologists toward adopting generics, especially in volume-driven practices. The prescribing mindset of gynecologists is now shaped not only by clinical efficacy but also by economic realities. Gynecologists are strategically balancing trust in quality with patient affordability, often incorporating both innovator and generic brands in their treatment portfolio. This dual approach reflects the broader shift from a "quality-centric" to a "value-centric" healthcare delivery model in India. Manufacturing standpoint, dydrogesterone synthesis remains complex, particularly for generics, which often lack the sophisticated stereochemical processes that define Duphaston. While this poses quality and consistency challenges for generic manufacturers, many have scaled production through aggressive pricing, wider distribution, and brand proliferation. manufacturing incentives, and brand positioning. The overall market behavior is now driven by a nexus of clinical science, commercial strategies, regulatory compliance, and behavioral economics. This review aims to map the current landscape of dydrogesterone prescription in India by analyzing sales data, gynecologist surveys, brand comparison metrics, and conceptual models. It highlights how the shift in prescriber psychology, patient demand, and pharma competition is redefining the future of progestogen therapy in gynecology.

Volume 13 Issue 12, December-2025

Pages : c617-c624